- Home
- INCY vs LECO Comparison
INCY vs LECO Comparison
Compare INCY & LECO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- LECO
- Stock Information
- Founded
- INCY 1991
- LECO 1895
- Country
- INCY United States
- LECO United States
- Employees
- INCY N/A
- LECO N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- LECO Industrial Machinery/Components
- Sector
- INCY Health Care
- LECO Industrials
- Exchange
- INCY Nasdaq
- LECO Nasdaq
- Market Cap
- INCY 13.4B
- LECO 11.3B
- IPO Year
- INCY 1993
- LECO N/A
- Fundamental
- Price
- INCY $68.07
- LECO $197.52
- Analyst Decision
- INCY Buy
- LECO Buy
- Analyst Count
- INCY 19
- LECO 7
- Target Price
- INCY $74.38
- LECO $233.00
- AVG Volume (30 Days)
- INCY 1.8M
- LECO 323.4K
- Earning Date
- INCY 04-29-2025
- LECO 04-24-2025
- Dividend Yield
- INCY N/A
- LECO 1.51%
- EPS Growth
- INCY N/A
- LECO N/A
- EPS
- INCY 0.15
- LECO 8.15
- Revenue
- INCY $4,241,216,999.00
- LECO $4,008,670,000.00
- Revenue This Year
- INCY $12.23
- LECO $3.03
- Revenue Next Year
- INCY $8.89
- LECO $5.33
- P/E Ratio
- INCY $454.93
- LECO $24.25
- Revenue Growth
- INCY 14.76
- LECO N/A
- 52 Week Low
- INCY $50.35
- LECO $169.51
- 52 Week High
- INCY $83.95
- LECO $261.13
- Technical
- Relative Strength Index (RSI)
- INCY 38.27
- LECO 45.56
- Support Level
- INCY $68.17
- LECO $191.86
- Resistance Level
- INCY $72.81
- LECO $204.64
- Average True Range (ATR)
- INCY 2.29
- LECO 5.86
- MACD
- INCY -0.32
- LECO -1.35
- Stochastic Oscillator
- INCY 8.61
- LECO 24.40
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About LECO Lincoln Electric Holdings Inc.
Lincoln Electric is a leading manufacturer of welding, cutting, and brazing products. The firm's portfolio of products includes arc-welding solutions, plasma and oxy-fuel cutting systems, and brazing and soldering alloys, as well as automation solutions. Lincoln Electric serves clients in the general fabrication, heavy industries, automotive, construction, shipbuilding, energy and process industries, among other end markets. Based in Cleveland, Ohio, Lincoln Electric has operations in 19 countries and has 11,000 employees worldwide. The company generated roughly $4.2 billion in sales in 2023.